| Journal: | Genetics and molecular biology |
| Database: | PERIÓDICA |
| System number: | 000459284 |
| ISSN: | 1415-4757 |
| Authors: | Velozo, Camila de Almeida1 Lamarão, Flávia Rachel Moreira2 Alvarado Arnez, Lucia Elena3 Cardoso, Cynthia Chester1 |
| Institutions: | 1Universidade Federal do Rio de Janeiro, Instituto de Biologia, Rio de Janeiro. Brasil 2GlaxoSmithKline, Rio de Janeiro. Brasil 3Universidad Franz Tamayo, Coordinación Nacional de Investigación, La Paz. Bolivia |
| Year: | 2022 |
| Volumen: | 45 |
| Number: | 3 |
| Country: | Brasil |
| Language: | Inglés |
| Document type: | Estado del arte |
| Approach: | Descriptivo |
| English abstract | The use of combined antiretroviral therapy (cART) has resulted in a remarkable reduction in morbidity and mortality of people living with HIV worldwide. Nevertheless, interindividual variations in drug response often impose a challenge to cART effectiveness. Although personalized therapeutic regimens may help overcome incidence of adverse reactions and therapeutic failure attributed to host factors, pharmacogenetic studies are often restricted to a few populations. Latin American countries accounted for 2.1 million people living with HIV and 1.4 million undergoing cART in 2020-21. The present review describes the state of art of HIV pharmacogenetics in this region and highlights that such analyses remain to be given the required relevance. A broad analysis of pharmacogenetic markers in Latin America could not only provide a better understanding of genetic structure of these populations, but might also be crucial to develop more informative dosing algorithms, applicable to non-European populations |
| Disciplines: | Biología, Medicina |
| Keyword: | Virus, Genética, Farmacología, VIH, Farmacogenética, América Latina, Terapia, Revisión bibliográfica |
| Keyword: | Virus, Genetics, Pharmacology, Therapy, HIV, Latin America, Pharmacogenetics, Bibliographic review |
| Full text: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
